« Feed you head | Main | Imaging Test May Diagnosis MS Early »

Serono MS drug's U.S. expansion plan on track-CEO

Europe's biggest biotechnology company is heavily reliant on its MS drug and investors were disappointed with third-quarter U.S. sales. Serono shares have risen by around a fifth this year, closing at 890 Swiss francs on Friday.

Read it here.

December 2, 2003 in economy, follow the money..., rebif, stocks | Permalink

Comments